132 related articles for article (PubMed ID: 35486994)
1. Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase.
Mei LC; Zhuo LS; Xu HC; Huang W; Hao GF; Yang GF
Eur J Med Chem; 2022 Jul; 237():114406. PubMed ID: 35486994
[TBL] [Abstract][Full Text] [Related]
2. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
[TBL] [Abstract][Full Text] [Related]
3. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
Zhuo LS; Wang MS; Wu FX; Xu HC; Gong Y; Yu ZC; Tian YG; Pang C; Hao GF; Huang W; Yang GF
J Med Chem; 2021 Oct; 64(20):15503-15514. PubMed ID: 34668694
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.
Gong Y; Wu FX; Wang MS; Xu HC; Zhuo LS; Yang GF; Huang W
Eur J Med Chem; 2022 Nov; 241():114654. PubMed ID: 35961071
[TBL] [Abstract][Full Text] [Related]
7. Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.
Wang ZZ; Wang MS; Wang F; Shi XX; Huang W; Hao GF; Yang GF
Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35649390
[TBL] [Abstract][Full Text] [Related]
8. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
10. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
[No Abstract] [Full Text] [Related]
11. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review.
Panchal I; Tripathi RKP; Parmar K; Yadav MR
Curr Top Med Chem; 2024; 24(1):3-30. PubMed ID: 38058091
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
[TBL] [Abstract][Full Text] [Related]
15. Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation.
Fan Y; Zhang Y; Liu Y; Jiang H; Zhou Y; Tang C; Fan W
Bioorg Med Chem Lett; 2022 May; 63():128646. PubMed ID: 35231576
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
17. Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.
Ito T; Kinoshita K; Tomizawa M; Shinohara S; Nishii H; Matsushita M; Hattori K; Kohchi Y; Kohchi M; Hayase T; Watanabe F; Hasegawa K; Tanaka H; Kuramoto S; Takanashi K; Oikawa N
J Med Chem; 2022 Sep; 65(18):12427-12444. PubMed ID: 36066182
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.
Sun M; Cai S; Li P; Zhang F; Zhang H; Zhou J
Bioorg Med Chem; 2020 Dec; 28(23):115811. PubMed ID: 33069129
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
